Home » ELIXIR PHARMACEUTICALS ACQUIRES LATE-STAGE PRODUCT FOR THE TREATMENT OF TYPE II DIABETES
ELIXIR PHARMACEUTICALS ACQUIRES LATE-STAGE PRODUCT FOR THE TREATMENT OF TYPE II DIABETES
Elixir Licenses Exclusive
U.S., Canadian and Latin American Rights from Kissei Pharmaceutical for Glufast;
Product Will Enter Growing $6 Billion Diabetes Prescription Pharmaceutical Market
Elixir Pharmaceuticals, Inc. announced today that the Company has signed a definitive
agreement with Kissei Pharmaceutical for the exclusive right to develop and commercialize
Glufast (mitiglinide calcium hydrate) in the United States, Canada, and Latin
America.
Genetic
Engineering News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
28Mar
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May